文献速递淋巴瘤

TP53基因组异常定义儿童B细胞非霍奇金淋巴瘤的不同风险组

Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.
PubMed 文献 · Leukemia · 2021-10-21

该研究在英国大型儿童B细胞非霍奇金淋巴瘤队列中评估TP53异常(突变、缺失和/或拷贝数中性杂合性缺失)的临床意义。TP53异常见于54.7%的病例,与显著更差的生存独立相关(PFS 70.0% vs 100%,p < 0.001;OS 78.0% vs 100%,p = 0.002)。在临床高危患者中,无TP53异常者生存优于有异常者(PFS 100% vs 55.6%,p = 0.005;OS 100% vs 66.7%,p = 0.019)。

要点

  • TP53异常在儿童B-NHL中占54.7%,与显著 inferior 生存独立相关。
  • 临床高危患者中,无TP53异常者PFS和OS均显著优于有异常者。
  • TP53异常可作为儿童B-NHL的新型分子风险分层指标。

核心结论

  • TP53异常定义儿童B-NHL的临床风险组,并提供新型分子风险分层工具。

研究设计与样本

  • 研究评估英国大型儿童B-NHL队列中TP53异常的临床意义及其对生存的影响。

主要发现

  • TP53异常存在于54.7%的病例,与显著更差的PFS(70.0% vs 100%,p < 0.001)和OS(78.0% vs 100%,p = 0.002)独立相关。
  • 临床高危患者中,无TP53异常者PFS为100% vs 55.6%(p = 0.005),OS为100% vs 66.7%(p = 0.019)。
  • 所有配对诊断/进展的伯基特淋巴瘤病例中,双等位基因TP53异常在诊断时已存在或在进展时获得。

临床怎么用

  • TP53异常可用于儿童B-NHL的分子风险分层,帮助制定更个性化的治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Newman AM, Zaka M, Zhou P, et al. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia. 2021. PMID: 34675373. doi:10.1038/s41375-021-01444-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。